What are the recommended dosing, contraindications, and monitoring parameters for amlodipine in adult patients?

Amlodipine: Dosing, Contraindications, and Monitoring

For adult hypertension, start amlodipine at 5 mg once daily (or 2.5 mg in elderly, frail, or hepatically impaired patients), with a maximum dose of 10 mg once daily; titrate every 7-14 days based on blood pressure response. 1

Recommended Dosing

Adults

Hypertension:

• Initial dose: 5 mg once daily 2, 3, 4, 5, 1
• Starting dose for special populations: 2.5 mg once daily for:
  • Small or fragile patients
  • Elderly patients
  • Hepatic insufficiency
  • When adding to existing antihypertensive therapy 1
• Maximum dose: 10 mg once daily 1
• Titration: Wait 7-14 days between dose adjustments, though more rapid titration is acceptable with frequent monitoring 1

Angina (chronic stable or vasospastic):

• Dose range: 5-10 mg once daily
• Lower doses (5 mg) suggested for elderly and hepatically impaired patients
• Most patients require 10 mg for adequate effect 1

Coronary artery disease:

• Dose range: 5-10 mg once daily
• Majority of patients in clinical trials required 10 mg 1

Pediatric Patients (6-17 years)

• Effective dose: 2.5-5 mg once daily
• Maximum studied dose: 5 mg daily (doses exceeding this have not been studied) 1

Pediatric Pulmonary Hypertension

For calcium channel blocker-responsive patients only:

• Starting dose: 0.1-0.3 mg/kg/day orally
• Dose range: 2.5-7.5 mg/day
• Maximum adult dose: 10 mg/day
• Always uptitrate from lower doses 6

Pharmacokinetic Considerations

Amlodipine has unique pharmacokinetic properties that distinguish it from other calcium channel blockers:

• Half-life: 30-50 hours (some sources cite 35-50 hours) 1, 7
• Time to steady state: 7-8 days of consecutive daily dosing 1
• Duration of action: >24 hours, providing continuous BP control even with missed doses 7
• Renal clearance: Very low (7 mL/min/mg), allowing usual dosing in renal impairment 1, 7

Factors affecting amlodipine concentration:

• Female sex: Women have higher dose-adjusted concentrations and use lower daily doses 8
• Age: Concentrations increase with age (40-60% increase in elderly) 1, 8
• Hepatic insufficiency: 40-60% increase in AUC; start with 2.5 mg 1
• Renal impairment: No significant effect; usual initial dose appropriate 1
• CYP3A4 inhibitors: Strong inhibitors (itraconazole, clarithromycin) may significantly increase concentrations 1
• CYP3A4*22 allele: Associated with higher concentrations 8

Contraindications and Precautions

Absolute Contraindications

• Known hypersensitivity to amlodipine or other dihydropyridines

Relative Contraindications and Cautions

Heart failure with reduced ejection fraction (HFrEF):

• Avoid in patients with pulmonary edema or severe LV dysfunction 2, 3, 4
• Amlodipine and felodipine are "reasonably well tolerated" in mild LV dysfunction, though evidence in UA/NSTEMI is limited 2, 4
• Unlike verapamil and diltiazem, amlodipine has minimal negative inotropic effects 4

Acute coronary syndromes:

• Use with caution in UA/NSTEMI; evidence base is limited compared to verapamil/diltiazem 2, 4
• Should not replace beta-blockers as first-line therapy
• May be used for symptom control when beta-blockers and nitrates are inadequate 4

Hypotension:

• Monitor carefully, especially in elderly and hepatically impaired patients
• Dose-related side effect 1

Drug interactions requiring dose adjustment:

• With simvastatin: Limit simvastatin to ≤20 mg when using amlodipine (77% increase in simvastatin exposure) 9, 1
• With CYP3A4 inhibitors: Consider lower starting doses with strong inhibitors 1
• With cyclosporine: Monitor cyclosporine levels (average 40% increase) 1
• With tacrolimus: Monitor levels closely (2.5-4 fold increase in CYP3A5 expressers) 1

Monitoring Parameters

Initial Assessment

• Baseline blood pressure (office and ideally ambulatory BP monitoring)
• Heart rate
• Hepatic function tests (if hepatic impairment suspected)
• Renal function (creatinine, eGFR)
• Electrocardiogram (baseline)

During Titration

• Blood pressure: Check 7-14 days after each dose adjustment 1
• Heart rate: Monitor for reflex tachycardia (though less common with amlodipine than other dihydropyridines)
• Symptoms: Assess for edema, dizziness, flushing, headache

Long-term Monitoring

Blood pressure control:

• Office BP measurements at each visit
• Consider 24-hour ambulatory BP monitoring for:
  • Confirming adequate 24-hour control 10, 11
  • Assessing dipping status
  • Evaluating BP variability (amlodipine reduces BP variability) 7
• Target: <130/80 mmHg for most adults 5, 12

Adverse effects surveillance:

• Peripheral edema: Most common dose-related side effect (1.8% at 2.5 mg, 10.8% at 10 mg); more common in women (14.6% vs 5.6% in men) 1
• Headache: Common, especially at higher doses 1
• Flushing: More common in women (4.5% vs 1.5% in men) 1
• Dizziness: Dose-related (1.1% at 2.5 mg, 3.4% at 5-10 mg) 1
• Palpitations: More common in women (3.3% vs 1.4% in men) 1

Laboratory monitoring:

• Routine laboratory tests are generally not required (amlodipine not associated with clinically significant changes) 1
• If using with other antihypertensives requiring monitoring (ACE inhibitors, ARBs, diuretics), follow those protocols 12

Special monitoring situations:

• Hepatic impairment: Monitor for increased drug effects; may need dose reduction
• Elderly patients: Monitor for orthostatic hypotension and increased adverse effects
• Combination therapy: When used with simvastatin, monitor for myopathy symptoms 9

Clinical Pearls

Advantages of amlodipine:

• Long half-life provides smooth 24-hour BP control 7
• Maintains BP control even with missed doses 7
• No dose adjustment needed in renal impairment 1
• Reduces BP variability 7
• Cost-effective compared to usual care 7
• Well-tolerated in combination therapy 13, 14

Common pitfalls to avoid:

• Don't use immediate-release nifedipine as a substitute; it has different safety profile
• Don't assume all calcium channel blockers are interchangeable; amlodipine has unique pharmacokinetics
• Don't overlook the need for lower starting doses in elderly, frail, or hepatically impaired patients
• Don't combine with high-dose simvastatin (>20 mg) 9
• Don't discontinue abruptly in patients with angina

Combination therapy considerations:

• ACE inhibitor + amlodipine superior to ACE inhibitor + hydrochlorothiazide for cardiovascular outcomes in high-risk patients (ACCOMPLISH trial) 13, 14
• Particularly effective in black patients when combined with thiazide diuretics 15
• Most hypertensive patients require ≥2 agents for adequate control 5, 15